February 28, 2019Tianjin Tanabe and Servier Tianjin
join hands to promote TENELIA® in ChinaTianjin Tanabe Seiyaku Co., Ltd. (hereinafter, Tianjin Tanabe; Head Office: Tianjin,China) and Servier Pharma (Tianjin) (Servier Tianjin; Head Office: Tianjin, China)
have today signed an exclusive strategic agreement to promote the type 2 diabetes
treatment drug TENELIA® (Teneligliptin) in mainland China. Tianjin Tanabe is a
consolidated subsidiary of Mitsubishi Tanabe Pharma Corporation (MTPC; HeadOffice: Osaka, Japan; President & Representative Director, CEO: Masayuki Mitsuka),and Servier Tianjin is a member of Les Laboratoires Servier Group (Servier; HeadOffice: Paris, France; President: Olivier LAUREAU). TENELIA® was developed byMTPC.
China has about 120 million people with diabetes* which is the world’s largest
populations of patients with type 2 diabetes. China includes nearly 30% of theworldwide total number of people with diabetes, and the number of people withdiabetes is expected to continue to increase. The collaboration with Servier Tianjin,
which has approximately 700 MRs in China specializing in diabetes and has a track insales extending over 40 years, is expected to contribute to the rapid market
penetration of TENELIA® and to the maximization of its product value.
TENELIA® is a DPP-4 inhibitor created by MTPC and is the first drug of its kind to
originate from Japan. TENELIA® suppresses glucagon release and increases insulin
release, subsequently lowering blood-glucose levels by selectively inhibiting theactivity of dipeptidyl peptidase-4 (DPP-4), an enzyme that inactivates glucagon-like
peptide-1 (GLP-1), a hormone excreted from the gastrointestinal tract in responseto food ingestion. TENELIA®, with its potent and sustained action, has made it highly
effective in lowering each of the blood glucose postprandial levels, as well as fastingblood glucose levels, with once-a-day administration. MTPC has completed thephase 3 clinical studies in China.
China, which is the second largest pharmaceuticals market in the world, is an
important market for both MTPC and Servier. Working together, the two companies
aim to attain better glycemic control for patients in China by providing a new option
for the treatment of diabetes.

1 / 2

*IDF：International Diabetes Federation

Mitsubishi Tanabe Pharma Corporation
Corporate Communications Department
Media contacts: TEL:+81 6 6205 5119
Investor contacts: TEL:+81 6 6205 5110

<Reference>
About Tianjin Tanabe Seiyaku Co., Ltd.
Tianjin Tanabe Seiyaku Co., Ltd. was founded in Tianjin, China, in 1993 through joint
financing from Tianjin Lisheng Pharmaceutical Co., Ltd. and MTPC. The company isengaged in the manufacture and sales of pharmaceuticals in China. As a corecompany of the MTPC group in China, the company seeks to contribute to medical
needs in China through the manufacture and sales of high quality pharmaceuticals
with the MTPC brand, particularly cardiovascular drugs, gastrointestinal drugs, andanti-allergic agents for patients in China.
About Servier Tianjin
Servier is an international pharmaceutical company governed by a nonprofit
foundation, with its headquarters in France (Suresnes). With a strong internationalpresence in 149 countries and a turnover of 4.152 billion euros in 2017, Servieremploys 21,700 people worldwide. Entirely independent, the Group reinvests 25
percent of its turnover (excluding generic drugs) in research and development anduses all of its profits for development. Corporate growth is driven by Servier’s
constant search for innovation in five areas of excellence: cardiovascular,
immune-inflammatory, neuropsychiatric diseases, cancer and diabetes. Servier alsoofferseHealthsolutionsbeyonddrug

www.servier.com

2 / 2

development.

More

information: